Company Description
Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic conditions with high unmet need in the United States.
The company’s pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH023 which is phase 1 clinical trial used to treat multiple high value autoimmune indications; and HS1940, which targets programmed cell death protein 1 (PD-1).
It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics.
The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023.
Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.
| Country | United States |
| Founded | 2017 |
| IPO Date | Jan 12, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Randy Milby |
Contact Details
Address: 1200 Route 22 East, Suite 2000 Bridgewater, New Jersey 08807 United States | |
| Phone | 908 270 8260 |
| Website | tharimmune.com |
Stock Details
| Ticker Symbol | THAR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 0001861657 |
| CUSIP Number | 432705200 |
| ISIN Number | US4327052001 |
| Employer ID | 84-2642541 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Randy D. Milby MBA | President, Chairman and Chief Executive Officer |
| Sireesh Appajosyula Pharm.D. | Chief Operating Officer and Director |
| Dong Kim | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 12, 2025 | 10-Q | Quarterly Report |
| May 9, 2025 | 8-K | Current Report |
| May 2, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 1, 2025 | ARS | Filing |
| Apr 30, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 30, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 28, 2025 | 8-K | Current Report |
| Apr 25, 2025 | 8-K | Current Report |
| Apr 10, 2025 | 8-K | Current Report |
| Apr 4, 2025 | 8-K | Current Report |